Maxion Therapeutics

#Acute inflammatory conditions #Financing #GPCRs #Maxion Therapeutics #Therapeutic Antibodies

Maxion Therapeutics raises $72m to advance KnotBody pipeline

Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases.  The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and… Read More

#Business & Investment #News